Navigation Links
Espion Visual Electrophysiology System

ProductsEspion Visual Electrophysiology System
Company Diagnosys, LLC
Item Espion Visual Electrophysiology System
Features 
  • Minimum System: Espion Console, PowerBloc, one stimulator. System includes headbox, software, manual, starter pack of electrodes and all cables
  • Portable (20lb, 9Kg), and self contained (all major electronics in one box)
  • Compact (12"x18"x14") and ergonomically designed to save desk space
  • Integrated bright 10.4 TFT LCD screen with infrared touch screen
  • Fast Pentium CPU running Windows 98 with 128Mb RAM, large HDD and 250Mb zip drive
  • Advanced real-time DSP processor based acquisition system
  • 5 integral computer controlled fully isolated differential amplifiers with digital low, high and band pass filters, DC input, (not AC coupled)
  • Sophisticated impedance measurement system allowing individual electrode checking
  • 10BaseT Ethernet connection (on PowerBloc) for simple interfacing to existing networks
  • USB, Parallel, RS232 (Isolated), 10BaseT network connections (on PowerBloc)
  • 5 integral computer controlled fully isolated differential amplifiers with digital low, high and band pass filters, DC input, (not AC coupled) and impedance measurement system
  • Infrared mouse and keyboard included
  • Predefined test protocols and the ability to create new custom protocols
  • Industry standard SQL database using an advanced interface for comprehensive data storage and retrieval
Description At the heart of the Diagnosys electrophysiology system is the Espion. This is an advanced modular system allowing it to support a wide variety of stimulators for different types of visual test.

Clinical Function Testing
The Espion system was designed from the ground up to easily perform all the current standard clinical visual function tests, ERG, VEP, PERG, Focal-ERG, EOG, Flash-VEP, Dark Adaptometry tests (depending on stimulator options). Being very portable, it allows the clinician to take the equipment to the patient, and even into the operating theater.

Vision Research
The software and hardware includes a multitude of extra features that make it ideal for research purposes in both human and animal environments. New protocols can easily be created with the ability to configure almost every stimulus, acquisition, amplifier and marker parameter way in excess of the clinical standard. Finally, new features and options can be added at customer request to help make the equipment fulfill your research requirements.
Info Diagnosys, LLC
Customer Service: (978) 486-9797
Web site: http://www.diagnosysllc.com/

Related medicine products :

1. Espion E2 Electrophysiology System
2. Vision Monitor Visual electrophysiology
3. Vision Monitor Visual Electrophysiology: MonEl1
4. Vision Monitor Visual Electrophysiology: MonEl2
5. Humphrey FDT Visual Field Instrument
6. AT20R Visual Function Tester
7. S-Series Cystourethroscope Visual Obturator
8. USA Elite System™ Visual Urethrotome Kit
9. USA Elite System™ Visual Urethrotome
10. Harmony™ Lux Advantage LA Surgical Lighting and Visualization System
11. UTAS Visual Diagnostic System
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes.
...aspiration holes and additional electrode tip insu...recise dissection with decreased risk of collatera... design options allow the choice between retractab...designs. Optimize specific surgical demands safely...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so
Medicine Products:
(Date:12/3/2008)..., HeadNorth Foundation has pledged $975,000 to Bu...support cutting-edge stem cell research. The fundi... Project, will support efforts by Dr. Evan Snyder,...k Tuszynski, Director, Center for Neural Repair at...tem cells to treat chronic spinal cord injuries. ,...
(Date:12/3/2008)..., A new study has found that a school-based asthm...fornia school district was shown to reduce symptom...o suffered from asthma were able to go to school. ...rnal of School Health . , Nearly 10% or 6.8 mill... the Centers for Disease Control and Prevention. T...
(Date:12/3/2008)... DALLAS, Dec. 3 BeaconEquity.com a...s making news today. , , Investors can vie...ing: http://www.BeaconEquity.com/m , , To...NYSE: SPC ), Williams-Sonoma Inc. (NYSE: WSM )...ght Express Corp. (NYSE: WXS ), Morgans Hotel Gr...
(Date:12/3/2008)... SAN FRANCISCO, Dec. 3 Canadian te... the brain health revolution on Thursday night whe... airs on the Canadian Broadcast,Corporation net...ame by,author Norman Doidge, MD, the documentary ...sticity and features the science, scientists, prod...
Breaking Medicine News(10 mins):Health News:Burnham and HeadNorth Foundation join forces to advance spinal cord research 2Health News:Study shows school-based program enables children and adolescents to better manage chronic disease 2Health News:Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: SPC, WSM, MRX, WXS, MHGC, DSPG 2Health News:Posit Science Featured in Canadian Documentary on the Brain 2
...roke in the Indian capital taking the toll since S... across north India. 'At least three people died... All the three were men and two of them apparently...' said Dinesh, in charge of the DDU police chowki....
...miserable, it drags you to worse ills in the futu...hers from Rush University Medical Center in Chicag...epressed are 40 times more likely to develop mild ...loss that is often a transitional stage between no...
...t healthcare systems in India has received a sever... chikungunya viral fever in the state. Last year... the mosquito-borne viral fever in the coastal dis...llam and Ernakulam. The present outbreak, which h...
...ne for cholera that can be well, eaten. Immunol...d his colleagues inserted the genetic material fro...xin, into a rice plant, whose genome has recently ...oxin and when the rice grains were fed to mice the...
Other Medicine News:Health News:Stress- Harms Now And Later 2Health News:Chikungunya Affects Kerala's Healthcare Status 2Health News:Vaccines On Your Plate 2
(Date:12/2/2008)...LA JOLLA, Calif., Dec. 2 TorreyPin...unced positive results from a 26 patient Phase II ...ent for xerostomia, or dry mouth, in patients with...int of a statistically significant increase in sal...hree doses: 10 mg, 15 mg, and 20 mg. These doses w...
(Date:12/1/2008)... , , , CHICAGO, Dec. 2 /PRNewswire-USNe...n mammography (PEM), a new technique for imaging t...y or a woman,s hormonal status, two factors that l... MRI at detecting cancer. Results will be presente...Society of North America (RSNA). , , "The ...
(Date:12/1/2008)...INDIANAPOLIS, Dec. 1 Roche announc...aluate differences in perceived pain and,discomfo...CU-CHEK blood,glucose monitoring systems and lanc...sults indicated that, overall, the ACCU-CHEK Aviva...ing systems and the ACCU-CHEK Multiclix, ACCU-CHEK...
(Date:12/1/2008)...PLYMOUTH MEETING, Pa., Dec. 1 /PRNewswire-FirstCal... announced that dosing of subjects has begun in st...ing dose Phase 1b study of trodusquemine (MSI-1436...36 is a novel therapeutic for the treatment of typ... peripherally to regulate insulin and leptin pathw...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Use of PressureWire 28R 29 Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature Two New Studies Report 1611 1Use of PressureWire 28R 29 Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature Two New Studies Report 1611 2Use of PressureWire 28R 29 Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature Two New Studies Report 1611 3Actor Greg Grunberg Meets With the Epilepsy Advocates in Washington DC 15380 1Actavis Receives Approval of Generic Wellbutrin SR 28R 29 and Zyban 28R 29 Tablets in the U S 4241 1Actavis Receives Approval of Generic Wellbutrin SR 28R 29 and Zyban 28R 29 Tablets in the U S 4241 2Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting 1610 1Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting 1610 2Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting 1610 3
...S WIRE)--Jul 9, 2007 - TransPharma Medical,Ltd., a...evelopment,and commercialization of drug products ...livery technology, announced today,promising resul...e,safety and pharmacokinetic profile of its ViaDer...rosis., A seven day, repeated dose application, pa...
...E)--Jul 8, 2007 - Late-breaking Phase III,clinical...al,Society on Thrombosis and Haemostasis (ISTH) Co...ieved superior efficacy in the,prevention of venou...e replacement surgery in a head-to-head comparison...tients in the RECORD3,(REgulation of Coagulation i...
Other Medicine Technology:TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 2TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5